BioSpace

Biotech IPOs approach ‘escape velocity’ barring yellow flags that could threaten rebound

Twenty-five biotechs have used the IPO route to go public this year—with five of those debuts occurring this month alone.
BioSpace

China’s Haisco forms immunology biotech with up to $1.5B from American VCs

Haisco Pharmaceutical Group has been on a deal hot streak this year, inking major deals with Eli Lilly, AbbVie and more. The ...
BioSpace

Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage fail

While Bausch + Lomb’s dual-action eye drops failed to outperform active comparators at day 29, the investigational asset ...
BioSpace

Lilly takes oral obesity race abroad with UK launch of Foundayo

Eli Lilly’s best play for Foundayo is to bring it overseas, a more price-sensitive market where the pharma can more readily ...
BioSpace

Preparing for Novartis showdown, Curium touts value of radiopharma supply resiliency

While Novartis’ Pluvicto is a blockbuster, Curium heads into talks with the FDA about the review of its rival drug candidate ...